Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:5518 |
Name | penis squamous cell carcinoma |
Definition | A penis carcinoma that has_material_basis_in squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:8008 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer penile cancer penis carcinoma penis squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02541903 | Phase II | Afatinib | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03357757 | Phase II | Avelumab + Valproic acid | Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) | Recruiting | CAN | 0 |
NCT03391479 | Phase II | Avelumab | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | Recruiting | CAN | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03774901 | Phase II | Avelumab | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (PULSE) | Recruiting | FRA | 0 |
NCT03943602 | Phase II | Cabozantinib | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) (CaboPen) | Unknown status | ITA | 0 |
NCT04357873 | Phase II | Pembrolizumab + Vorinostat | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) | Active, not recruiting | FRA | 0 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |